Monte Rosa Therapeutics (GLUE) Operating Expenses (2020 - 2026)

Monte Rosa Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $54.2 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 32.65% year-over-year to $54.2 million; the TTM figure through Mar 2026 stood at $191.2 million (up 18.32% YoY), while the FY2025 annual figure was $177.9 million, up 13.49% from the prior year.
• Operating Expenses was $54.2 million for Q1 2026 at Monte Rosa Therapeutics, up from $52.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $54.2 million in Q1 2026 to a low of $24.3 million in Q1 2022.
• Historically, Operating Expenses has averaged $37.9 million across 5 years, with a median of $37.0 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses surged 111.25% in 2022, then retreated 3.31% in 2024.
• A 5-year view of Operating Expenses shows it stood at $32.5 million in 2022, then climbed by 7.31% to $34.9 million in 2023, then surged by 36.66% to $47.6 million in 2024, then increased by 10.19% to $52.5 million in 2025, then increased by 3.33% to $54.2 million in 2026.
• The last three Operating Expenses figures came in at $54.2 million (Q1 2026), $52.5 million (Q4 2025), and $45.7 million (Q3 2025), per Business Quant data.